Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.37 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.32 |
| ▸ | HPGD | P15428 | 4/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17466611 | 0.86 | DRD2 (0.47) | DRD2DRD4DRD3HRH4CLK1 | |
| SCHEMBL9570100 | 0.83 | DRD2 (0.45) | DRD2DRD4DRD3HRH4CLK1 | |
| SCHEMBL12224868 | 0.83 | DRD2 (0.45) | DRD2DRD4DRD3HRH4CLK1 | |
| SCHEMBL9966056 | 0.79 | DRD2 (0.47) | DRD2DRD4DRD3HRH4CLK1 | |
| SCHEMBL12223303 | 0.79 | DRD2 (0.47) | DRD2DRD4DRD3HRH4CLK1 | |
| SCHEMBL7969572 | 0.76 | HRH4 (0.42) | DRD2DRD4DRD3HRH4CLK1 | |
| SCHEMBL31361452 | 0.75 | DRD2 (0.44) | DRD2DRD4DRD3HRH4CLK1 | |
| SCHEMBL29988623 | 0.75 | DRD2 (0.44) | DRD2DRD4DRD3HRH4CLK1 | |
| SCHEMBL3523864 | 0.75 | DRD2 (0.44) | DRD2DRD4DRD3HRH4CLK1 | |
| SCHEMBL12196978 | 0.75 | DRD2 (0.44) | DRD2DRD4DRD3HRH4CLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115611-A1 | CRYSTALLINE FORMS OF 8-(2-FLUOROBENZYL)-6-(3-(TRIFLUOROMETHYL)-1H-1,2,4-TRIAZOL-5-YL)IMIDAZO[1,2-a]PYRAZINE AS sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2025-04-10 | — | — | US | disclosed |
| US-12122782-B2 | Crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as sGC stimulators | TISENTO THERAPEUTICS INC. (US) | 2024-10-22 | — | — | US | disclosed |
| US-20230095799-A1 | CRYSTALLINE FORMS OF AN sGC STIMULATOR | TISENTO THERAPEUTICS INC. | 2023-03-30 | — | — | US | disclosed |
| US-11466015-B2 | Crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| US-6174877-B1 | EXCELLANT BACTERICIDES, ORAL ABSORBABILITY AND STABILITY; IMPROVE THE STABILITY TO RENAL DEHYDROPEPTIDASE I (DHP-I); 2-(2-(N-HETEROCYCLIC-ETHYLTHIO-) DERIVATIVES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-01-16 | — | — | US | disclosed |
| US-5270322-A | Imidazo[1,2-a]pyridines, pharmaceutical compositions containing these compounds and processes for preparing them | DR. KARL THOMAE GMBH (DE) | 1993-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12122782-B2 | Crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as sGC stimulators | GUCY1A2, GUCY1B2, GUCY1A1 | DRD2 4709/4885DRD4 4805/4885DRD3 4806/4885 |
| US-20230095799-A1 | CRYSTALLINE FORMS OF AN sGC STIMULATOR | GUCY1A2, GUCY1B2, GUCY1A1 | DRD2 4819/4885DRD4 4831/4885DRD3 4853/4885 |
| US-11466015-B2 | Crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as sGC stimulators | GUCY1A2, GUCY1B2, GUCY1A1 | DRD2 4709/4885DRD4 4805/4885DRD3 4806/4885 |
| US-20250115611-A1 | CRYSTALLINE FORMS OF 8-(2-FLUOROBENZYL)-6-(3-(TRIFLUOROMETHYL)-1H-1,2,4-TRIAZOL-5-YL)IMIDAZO[1,2-a]PYRAZINE AS sGC STIMULATORS | GUCY1A2, GUCY1B2, GUCY1A1 | DRD2 4709/4885DRD4 4805/4885DRD3 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.